

Global Immune Checkpoint Inhibitors Market Growth 2025-2031

<https://marketpublishers.com/r/G614D53F12AEN.html>

Date: October 2025

Pages: 96

Price: US\$ 3,660.00 (Single User License)

ID: G614D53F12AEN

Abstracts

The global Immune Checkpoint Inhibitors market size is predicted to grow from US\$ 18880 million in 2025 to US\$ 47640 million in 2031; it is expected to grow at a CAGR of 16.7% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.

United States market for Immune Checkpoint Inhibitors is estimated to increase from US\$ million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Immune Checkpoint Inhibitors is estimated to increase from US\$

million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Immune Checkpoint Inhibitors is estimated to increase from US\$ million in 2024 to US\$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Immune Checkpoint Inhibitors players cover Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the ?Immune Checkpoint Inhibitors Industry Forecast? looks at past sales and reviews total world Immune Checkpoint Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Immune Checkpoint Inhibitors sales for 2025 through 2031. With Immune Checkpoint Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Immune Checkpoint Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Immune Checkpoint Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immune Checkpoint Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Immune Checkpoint Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immune Checkpoint Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immune Checkpoint Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of Immune Checkpoint Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

PD-1/PD-L1

CTLA-4

Segmentation by Application:

Lung Cancer

Colorectal Cancer

Breast Cancer

Prostate Cancer

Melanoma

Blood Cancer

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Bristol Myer Squibb

AstraZeneca

Merck

Roche / Genentech

Ono Pharmaceutical

Regeneron

Innovent

Hengrui Medicine

Junshi Biosciences

Key Questions Addressed in this Report

What is the 10-year outlook for the global Immune Checkpoint Inhibitors market?

What factors are driving Immune Checkpoint Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Immune Checkpoint Inhibitors market opportunities vary by end market size?

How does Immune Checkpoint Inhibitors break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Immune Checkpoint Inhibitors Annual Sales 2020-2031
 - 2.1.2 World Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region, 2020, 2024 & 2031
 - 2.1.3 World Current & Future Analysis for Immune Checkpoint Inhibitors by Country/Region, 2020, 2024 & 2031
- 2.2 Immune Checkpoint Inhibitors Segment by Type
 - 2.2.1 PD-1/PD-L1
 - 2.2.2 CTLA-4
- 2.3 Immune Checkpoint Inhibitors Sales by Type
 - 2.3.1 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2020-2025)
 - 2.3.2 Global Immune Checkpoint Inhibitors Revenue and Market Share by Type (2020-2025)
 - 2.3.3 Global Immune Checkpoint Inhibitors Sale Price by Type (2020-2025)
- 2.4 Immune Checkpoint Inhibitors Segment by Application
 - 2.4.1 Lung Cancer
 - 2.4.2 Colorectal Cancer
 - 2.4.3 Breast Cancer
 - 2.4.4 Prostate Cancer
 - 2.4.5 Melanoma
 - 2.4.6 Blood Cancer
 - 2.4.7 Other
- 2.5 Immune Checkpoint Inhibitors Sales by Application
 - 2.5.1 Global Immune Checkpoint Inhibitors Sale Market Share by Application

(2020-2025)

2.5.2 Global Immune Checkpoint Inhibitors Revenue and Market Share by Application

(2020-2025)

2.5.3 Global Immune Checkpoint Inhibitors Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Immune Checkpoint Inhibitors Breakdown Data by Company

3.1.1 Global Immune Checkpoint Inhibitors Annual Sales by Company (2020-2025)

3.1.2 Global Immune Checkpoint Inhibitors Sales Market Share by Company

(2020-2025)

3.2 Global Immune Checkpoint Inhibitors Annual Revenue by Company (2020-2025)

3.2.1 Global Immune Checkpoint Inhibitors Revenue by Company (2020-2025)

3.2.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Company

(2020-2025)

3.3 Global Immune Checkpoint Inhibitors Sale Price by Company

3.4 Key Manufacturers Immune Checkpoint Inhibitors Producing Area Distribution,
Sales Area, Product Type

3.4.1 Key Manufacturers Immune Checkpoint Inhibitors Product Location Distribution

3.4.2 Players Immune Checkpoint Inhibitors Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR IMMUNE CHECKPOINT INHIBITORS BY GEOGRAPHIC REGION

4.1 World Historic Immune Checkpoint Inhibitors Market Size by Geographic Region
(2020-2025)

4.1.1 Global Immune Checkpoint Inhibitors Annual Sales by Geographic Region

(2020-2025)

4.1.2 Global Immune Checkpoint Inhibitors Annual Revenue by Geographic Region

(2020-2025)

4.2 World Historic Immune Checkpoint Inhibitors Market Size by Country/Region
(2020-2025)

4.2.1 Global Immune Checkpoint Inhibitors Annual Sales by Country/Region

(2020-2025)

4.2.2 Global Immune Checkpoint Inhibitors Annual Revenue by Country/Region (2020-2025)

4.3 Americas Immune Checkpoint Inhibitors Sales Growth

4.4 APAC Immune Checkpoint Inhibitors Sales Growth

4.5 Europe Immune Checkpoint Inhibitors Sales Growth

4.6 Middle East & Africa Immune Checkpoint Inhibitors Sales Growth

5 AMERICAS

5.1 Americas Immune Checkpoint Inhibitors Sales by Country

5.1.1 Americas Immune Checkpoint Inhibitors Sales by Country (2020-2025)

5.1.2 Americas Immune Checkpoint Inhibitors Revenue by Country (2020-2025)

5.2 Americas Immune Checkpoint Inhibitors Sales by Type (2020-2025)

5.3 Americas Immune Checkpoint Inhibitors Sales by Application (2020-2025)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Immune Checkpoint Inhibitors Sales by Region

6.1.1 APAC Immune Checkpoint Inhibitors Sales by Region (2020-2025)

6.1.2 APAC Immune Checkpoint Inhibitors Revenue by Region (2020-2025)

6.2 APAC Immune Checkpoint Inhibitors Sales by Type (2020-2025)

6.3 APAC Immune Checkpoint Inhibitors Sales by Application (2020-2025)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Immune Checkpoint Inhibitors by Country

7.1.1 Europe Immune Checkpoint Inhibitors Sales by Country (2020-2025)

7.1.2 Europe Immune Checkpoint Inhibitors Revenue by Country (2020-2025)

- 7.2 Europe Immune Checkpoint Inhibitors Sales by Type (2020-2025)
- 7.3 Europe Immune Checkpoint Inhibitors Sales by Application (2020-2025)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Immune Checkpoint Inhibitors by Country
 - 8.1.1 Middle East & Africa Immune Checkpoint Inhibitors Sales by Country (2020-2025)
 - 8.1.2 Middle East & Africa Immune Checkpoint Inhibitors Revenue by Country (2020-2025)
- 8.2 Middle East & Africa Immune Checkpoint Inhibitors Sales by Type (2020-2025)
- 8.3 Middle East & Africa Immune Checkpoint Inhibitors Sales by Application (2020-2025)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Immune Checkpoint Inhibitors
- 10.3 Manufacturing Process Analysis of Immune Checkpoint Inhibitors
- 10.4 Industry Chain Structure of Immune Checkpoint Inhibitors

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Immune Checkpoint Inhibitors Distributors
- 11.3 Immune Checkpoint Inhibitors Customer

12 WORLD FORECAST REVIEW FOR IMMUNE CHECKPOINT INHIBITORS BY GEOGRAPHIC REGION

- 12.1 Global Immune Checkpoint Inhibitors Market Size Forecast by Region
 - 12.1.1 Global Immune Checkpoint Inhibitors Forecast by Region (2026-2031)
 - 12.1.2 Global Immune Checkpoint Inhibitors Annual Revenue Forecast by Region (2026-2031)
- 12.2 Americas Forecast by Country (2026-2031)
- 12.3 APAC Forecast by Region (2026-2031)
- 12.4 Europe Forecast by Country (2026-2031)
- 12.5 Middle East & Africa Forecast by Country (2026-2031)
- 12.6 Global Immune Checkpoint Inhibitors Forecast by Type (2026-2031)
- 12.7 Global Immune Checkpoint Inhibitors Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

- 13.1 Bristol Myer Squibb
 - 13.1.1 Bristol Myer Squibb Company Information
 - 13.1.2 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Portfolios and Specifications
 - 13.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.1.4 Bristol Myer Squibb Main Business Overview
 - 13.1.5 Bristol Myer Squibb Latest Developments
- 13.2 AstraZeneca
 - 13.2.1 AstraZeneca Company Information
 - 13.2.2 AstraZeneca Immune Checkpoint Inhibitors Product Portfolios and Specifications
 - 13.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.2.4 AstraZeneca Main Business Overview
 - 13.2.5 AstraZeneca Latest Developments
- 13.3 Merck

- 13.3.1 Merck Company Information
- 13.3.2 Merck Immune Checkpoint Inhibitors Product Portfolios and Specifications
- 13.3.3 Merck Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
- 13.3.4 Merck Main Business Overview
- 13.3.5 Merck Latest Developments
- 13.4 Roche / Genentech
 - 13.4.1 Roche / Genentech Company Information
 - 13.4.2 Roche / Genentech Immune Checkpoint Inhibitors Product Portfolios and Specifications
 - 13.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.4.4 Roche / Genentech Main Business Overview
 - 13.4.5 Roche / Genentech Latest Developments
- 13.5 Ono Pharmaceutical
 - 13.5.1 Ono Pharmaceutical Company Information
 - 13.5.2 Ono Pharmaceutical Immune Checkpoint Inhibitors Product Portfolios and Specifications
 - 13.5.3 Ono Pharmaceutical Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.5.4 Ono Pharmaceutical Main Business Overview
 - 13.5.5 Ono Pharmaceutical Latest Developments
- 13.6 Regeneron
 - 13.6.1 Regeneron Company Information
 - 13.6.2 Regeneron Immune Checkpoint Inhibitors Product Portfolios and Specifications
 - 13.6.3 Regeneron Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.6.4 Regeneron Main Business Overview
 - 13.6.5 Regeneron Latest Developments
- 13.7 Innovent
 - 13.7.1 Innovent Company Information
 - 13.7.2 Innovent Immune Checkpoint Inhibitors Product Portfolios and Specifications
 - 13.7.3 Innovent Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)
 - 13.7.4 Innovent Main Business Overview
 - 13.7.5 Innovent Latest Developments
- 13.8 Hengrui Medicine
 - 13.8.1 Hengrui Medicine Company Information
 - 13.8.2 Hengrui Medicine Immune Checkpoint Inhibitors Product Portfolios and

Specifications

13.8.3 Hengrui Medicine Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)

13.8.4 Hengrui Medicine Main Business Overview

13.8.5 Hengrui Medicine Latest Developments

13.9 Junshi Biosciences

13.9.1 Junshi Biosciences Company Information

13.9.2 Junshi Biosciences Immune Checkpoint Inhibitors Product Portfolios and Specifications

13.9.3 Junshi Biosciences Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025)

13.9.4 Junshi Biosciences Main Business Overview

13.9.5 Junshi Biosciences Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Immune Checkpoint Inhibitors Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Table 2. Immune Checkpoint Inhibitors Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of PD-1/PD-L1

Table 4. Major Players of CTLA-4

Table 5. Global Immune Checkpoint Inhibitors Sales by Type (2020-2025) & (K Units)

Table 6. Global Immune Checkpoint Inhibitors Sales Market Share by Type (2020-2025)

Table 7. Global Immune Checkpoint Inhibitors Revenue by Type (2020-2025) & (\$ million)

Table 8. Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2020-2025)

Table 9. Global Immune Checkpoint Inhibitors Sale Price by Type (2020-2025) & (USD/Unit)

Table 10. Global Immune Checkpoint Inhibitors Sale by Application (2020-2025) & (K Units)

Table 11. Global Immune Checkpoint Inhibitors Sale Market Share by Application (2020-2025)

Table 12. Global Immune Checkpoint Inhibitors Revenue by Application (2020-2025) & (\$ million)

Table 13. Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2020-2025)

Table 14. Global Immune Checkpoint Inhibitors Sale Price by Application (2020-2025) & (USD/Unit)

Table 15. Global Immune Checkpoint Inhibitors Sales by Company (2020-2025) & (K Units)

Table 16. Global Immune Checkpoint Inhibitors Sales Market Share by Company (2020-2025)

Table 17. Global Immune Checkpoint Inhibitors Revenue by Company (2020-2025) & (\$ millions)

Table 18. Global Immune Checkpoint Inhibitors Revenue Market Share by Company (2020-2025)

Table 19. Global Immune Checkpoint Inhibitors Sale Price by Company (2020-2025) & (USD/Unit)

Table 20. Key Manufacturers Immune Checkpoint Inhibitors Producing Area Distribution

and Sales Area

Table 21. Players Immune Checkpoint Inhibitors Products Offered

Table 22. Immune Checkpoint Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global Immune Checkpoint Inhibitors Sales by Geographic Region (2020-2025) & (K Units)

Table 26. Global Immune Checkpoint Inhibitors Sales Market Share Geographic Region (2020-2025)

Table 27. Global Immune Checkpoint Inhibitors Revenue by Geographic Region (2020-2025) & (\$ millions)

Table 28. Global Immune Checkpoint Inhibitors Revenue Market Share by Geographic Region (2020-2025)

Table 29. Global Immune Checkpoint Inhibitors Sales by Country/Region (2020-2025) & (K Units)

Table 30. Global Immune Checkpoint Inhibitors Sales Market Share by Country/Region (2020-2025)

Table 31. Global Immune Checkpoint Inhibitors Revenue by Country/Region (2020-2025) & (\$ millions)

Table 32. Global Immune Checkpoint Inhibitors Revenue Market Share by Country/Region (2020-2025)

Table 33. Americas Immune Checkpoint Inhibitors Sales by Country (2020-2025) & (K Units)

Table 34. Americas Immune Checkpoint Inhibitors Sales Market Share by Country (2020-2025)

Table 35. Americas Immune Checkpoint Inhibitors Revenue by Country (2020-2025) & (\$ millions)

Table 36. Americas Immune Checkpoint Inhibitors Sales by Type (2020-2025) & (K Units)

Table 37. Americas Immune Checkpoint Inhibitors Sales by Application (2020-2025) & (K Units)

Table 38. APAC Immune Checkpoint Inhibitors Sales by Region (2020-2025) & (K Units)

Table 39. APAC Immune Checkpoint Inhibitors Sales Market Share by Region (2020-2025)

Table 40. APAC Immune Checkpoint Inhibitors Revenue by Region (2020-2025) & (\$ millions)

Table 41. APAC Immune Checkpoint Inhibitors Sales by Type (2020-2025) & (K Units)

Table 42. APAC Immune Checkpoint Inhibitors Sales by Application (2020-2025) & (K Units)

Table 43. Europe Immune Checkpoint Inhibitors Sales by Country (2020-2025) & (K Units)

Table 44. Europe Immune Checkpoint Inhibitors Revenue by Country (2020-2025) & (\$ millions)

Table 45. Europe Immune Checkpoint Inhibitors Sales by Type (2020-2025) & (K Units)

Table 46. Europe Immune Checkpoint Inhibitors Sales by Application (2020-2025) & (K Units)

Table 47. Middle East & Africa Immune Checkpoint Inhibitors Sales by Country (2020-2025) & (K Units)

Table 48. Middle East & Africa Immune Checkpoint Inhibitors Revenue Market Share by Country (2020-2025)

Table 49. Middle East & Africa Immune Checkpoint Inhibitors Sales by Type (2020-2025) & (K Units)

Table 50. Middle East & Africa Immune Checkpoint Inhibitors Sales by Application (2020-2025) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities of Immune Checkpoint Inhibitors

Table 52. Key Market Challenges & Risks of Immune Checkpoint Inhibitors

Table 53. Key Industry Trends of Immune Checkpoint Inhibitors

Table 54. Immune Checkpoint Inhibitors Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. Immune Checkpoint Inhibitors Distributors List

Table 57. Immune Checkpoint Inhibitors Customer List

Table 58. Global Immune Checkpoint Inhibitors Sales Forecast by Region (2026-2031) & (K Units)

Table 59. Global Immune Checkpoint Inhibitors Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 60. Americas Immune Checkpoint Inhibitors Sales Forecast by Country (2026-2031) & (K Units)

Table 61. Americas Immune Checkpoint Inhibitors Annual Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 62. APAC Immune Checkpoint Inhibitors Sales Forecast by Region (2026-2031) & (K Units)

Table 63. APAC Immune Checkpoint Inhibitors Annual Revenue Forecast by Region (2026-2031) & (\$ millions)

Table 64. Europe Immune Checkpoint Inhibitors Sales Forecast by Country (2026-2031) & (K Units)

Table 65. Europe Immune Checkpoint Inhibitors Revenue Forecast by Country

(2026-2031) & (\$ millions)

Table 66. Middle East & Africa Immune Checkpoint Inhibitors Sales Forecast by Country (2026-2031) & (K Units)

Table 67. Middle East & Africa Immune Checkpoint Inhibitors Revenue Forecast by Country (2026-2031) & (\$ millions)

Table 68. Global Immune Checkpoint Inhibitors Sales Forecast by Type (2026-2031) & (K Units)

Table 69. Global Immune Checkpoint Inhibitors Revenue Forecast by Type (2026-2031) & (\$ millions)

Table 70. Global Immune Checkpoint Inhibitors Sales Forecast by Application (2026-2031) & (K Units)

Table 71. Global Immune Checkpoint Inhibitors Revenue Forecast by Application (2026-2031) & (\$ millions)

Table 72. Bristol Myer Squibb Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 73. Bristol Myer Squibb Immune Checkpoint Inhibitors Product Portfolios and Specifications

Table 74. Bristol Myer Squibb Immune Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 75. Bristol Myer Squibb Main Business

Table 76. Bristol Myer Squibb Latest Developments

Table 77. AstraZeneca Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 78. AstraZeneca Immune Checkpoint Inhibitors Product Portfolios and Specifications

Table 79. AstraZeneca Immune Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 80. AstraZeneca Main Business

Table 81. AstraZeneca Latest Developments

Table 82. Merck Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 83. Merck Immune Checkpoint Inhibitors Product Portfolios and Specifications

Table 84. Merck Immune Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 85. Merck Main Business

Table 86. Merck Latest Developments

Table 87. Roche / Genentech Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 88. Roche / Genentech Immune Checkpoint Inhibitors Product Portfolios and

Specifications

Table 89. Roche / Genentech Immune Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 90. Roche / Genentech Main Business

Table 91. Roche / Genentech Latest Developments

Table 92. Ono Pharmaceutical Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 93. Ono Pharmaceutical Immune Checkpoint Inhibitors Product Portfolios and Specifications

Table 94. Ono Pharmaceutical Immune Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 95. Ono Pharmaceutical Main Business

Table 96. Ono Pharmaceutical Latest Developments

Table 97. Regeneron Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 98. Regeneron Immune Checkpoint Inhibitors Product Portfolios and Specifications

Table 99. Regeneron Immune Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 100. Regeneron Main Business

Table 101. Regeneron Latest Developments

Table 102. Innovent Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 103. Innovent Immune Checkpoint Inhibitors Product Portfolios and Specifications

Table 104. Innovent Immune Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 105. Innovent Main Business

Table 106. Innovent Latest Developments

Table 107. Hengrui Medicine Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 108. Hengrui Medicine Immune Checkpoint Inhibitors Product Portfolios and Specifications

Table 109. Hengrui Medicine Immune Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 110. Hengrui Medicine Main Business

Table 111. Hengrui Medicine Latest Developments

Table 112. Junshi Biosciences Basic Information, Immune Checkpoint Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 113. Junshi Biosciences Immune Checkpoint Inhibitors Product Portfolios and

Specifications

Table 114. Junshi Biosciences Immune Checkpoint Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 115. Junshi Biosciences Main Business

Table 116. Junshi Biosciences Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Immune Checkpoint Inhibitors
- Figure 2. Immune Checkpoint Inhibitors Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Immune Checkpoint Inhibitors Sales Growth Rate 2020-2031 (K Units)
- Figure 7. Global Immune Checkpoint Inhibitors Revenue Growth Rate 2020-2031 (\$ millions)
- Figure 8. Immune Checkpoint Inhibitors Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)
- Figure 9. Immune Checkpoint Inhibitors Sales Market Share by Country/Region (2024)
- Figure 10. Immune Checkpoint Inhibitors Sales Market Share by Country/Region (2020, 2024 & 2031)
- Figure 11. Product Picture of PD-1/PD-L1
- Figure 12. Product Picture of CTLA-4
- Figure 13. Global Immune Checkpoint Inhibitors Sales Market Share by Type in 2025
- Figure 14. Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2020-2025)
- Figure 15. Immune Checkpoint Inhibitors Consumed in Lung Cancer
- Figure 16. Global Immune Checkpoint Inhibitors Market: Lung Cancer (2020-2025) & (K Units)
- Figure 17. Immune Checkpoint Inhibitors Consumed in Colorectal Cancer
- Figure 18. Global Immune Checkpoint Inhibitors Market: Colorectal Cancer (2020-2025) & (K Units)
- Figure 19. Immune Checkpoint Inhibitors Consumed in Breast Cancer
- Figure 20. Global Immune Checkpoint Inhibitors Market: Breast Cancer (2020-2025) & (K Units)
- Figure 21. Immune Checkpoint Inhibitors Consumed in Prostate Cancer
- Figure 22. Global Immune Checkpoint Inhibitors Market: Prostate Cancer (2020-2025) & (K Units)
- Figure 23. Immune Checkpoint Inhibitors Consumed in Melanoma
- Figure 24. Global Immune Checkpoint Inhibitors Market: Melanoma (2020-2025) & (K Units)
- Figure 25. Immune Checkpoint Inhibitors Consumed in Blood Cancer
- Figure 26. Global Immune Checkpoint Inhibitors Market: Blood Cancer (2020-2025) &

(K Units)

Figure 27. Immune Checkpoint Inhibitors Consumed in Other

Figure 28. Global Immune Checkpoint Inhibitors Market: Other (2020-2025) & (K Units)

Figure 29. Global Immune Checkpoint Inhibitors Sale Market Share by Application (2024)

Figure 30. Global Immune Checkpoint Inhibitors Revenue Market Share by Application in 2025

Figure 31. Immune Checkpoint Inhibitors Sales by Company in 2025 (K Units)

Figure 32. Global Immune Checkpoint Inhibitors Sales Market Share by Company in 2025

Figure 33. Immune Checkpoint Inhibitors Revenue by Company in 2025 (\$ millions)

Figure 34. Global Immune Checkpoint Inhibitors Revenue Market Share by Company in 2025

Figure 35. Global Immune Checkpoint Inhibitors Sales Market Share by Geographic Region (2020-2025)

Figure 36. Global Immune Checkpoint Inhibitors Revenue Market Share by Geographic Region in 2025

Figure 37. Americas Immune Checkpoint Inhibitors Sales 2020-2025 (K Units)

Figure 38. Americas Immune Checkpoint Inhibitors Revenue 2020-2025 (\$ millions)

Figure 39. APAC Immune Checkpoint Inhibitors Sales 2020-2025 (K Units)

Figure 40. APAC Immune Checkpoint Inhibitors Revenue 2020-2025 (\$ millions)

Figure 41. Europe Immune Checkpoint Inhibitors Sales 2020-2025 (K Units)

Figure 42. Europe Immune Checkpoint Inhibitors Revenue 2020-2025 (\$ millions)

Figure 43. Middle East & Africa Immune Checkpoint Inhibitors Sales 2020-2025 (K Units)

Figure 44. Middle East & Africa Immune Checkpoint Inhibitors Revenue 2020-2025 (\$ millions)

Figure 45. Americas Immune Checkpoint Inhibitors Sales Market Share by Country in 2025

Figure 46. Americas Immune Checkpoint Inhibitors Revenue Market Share by Country (2020-2025)

Figure 47. Americas Immune Checkpoint Inhibitors Sales Market Share by Type (2020-2025)

Figure 48. Americas Immune Checkpoint Inhibitors Sales Market Share by Application (2020-2025)

Figure 49. United States Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 50. Canada Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 51. Mexico Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 52. Brazil Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 53. APAC Immune Checkpoint Inhibitors Sales Market Share by Region in 2025

Figure 54. APAC Immune Checkpoint Inhibitors Revenue Market Share by Region (2020-2025)

Figure 55. APAC Immune Checkpoint Inhibitors Sales Market Share by Type (2020-2025)

Figure 56. APAC Immune Checkpoint Inhibitors Sales Market Share by Application (2020-2025)

Figure 57. China Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 58. Japan Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 59. South Korea Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 60. Southeast Asia Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 61. India Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 62. Australia Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 63. China Taiwan Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 64. Europe Immune Checkpoint Inhibitors Sales Market Share by Country in 2025

Figure 65. Europe Immune Checkpoint Inhibitors Revenue Market Share by Country (2020-2025)

Figure 66. Europe Immune Checkpoint Inhibitors Sales Market Share by Type (2020-2025)

Figure 67. Europe Immune Checkpoint Inhibitors Sales Market Share by Application (2020-2025)

Figure 68. Germany Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 69. France Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 70. UK Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 71. Italy Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 72. Russia Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 73. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Country (2020-2025)

Figure 74. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Type (2020-2025)

Figure 75. Middle East & Africa Immune Checkpoint Inhibitors Sales Market Share by Application (2020-2025)

Figure 76. Egypt Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 77. South Africa Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 78. Israel Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 79. Turkey Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 80. GCC Countries Immune Checkpoint Inhibitors Revenue Growth 2020-2025 (\$ millions)

Figure 81. Manufacturing Cost Structure Analysis of Immune Checkpoint Inhibitors in 2025

Figure 82. Manufacturing Process Analysis of Immune Checkpoint Inhibitors

Figure 83. Industry Chain Structure of Immune Checkpoint Inhibitors

Figure 84. Channels of Distribution

Figure 85. Global Immune Checkpoint Inhibitors Sales Market Forecast by Region (2026-2031)

Figure 86. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Region (2026-2031)

Figure 87. Global Immune Checkpoint Inhibitors Sales Market Share Forecast by Type (2026-2031)

Figure 88. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Type (2026-2031)

Figure 89. Global Immune Checkpoint Inhibitors Sales Market Share Forecast by Application (2026-2031)

Figure 90. Global Immune Checkpoint Inhibitors Revenue Market Share Forecast by Application (2026-2031)

I would like to order

Product name: Global Immune Checkpoint Inhibitors Market Growth 2025-2031

Product link: <https://marketpublishers.com/r/G614D53F12AEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G614D53F12AEN.html>